. Author manuscript; available in PMC: 2018 Oct 1.

Published in final edited form as: Clin Cancer Res. 2017 Jun 27;23(19):5745–5756. doi: 10.1158/1078-0432.CCR-16-2844

Table 5.

Multivariable Cox proportional hazard results for overall survival in single agent bevacizumab and lomustine monotherapy (BELOB) using ADC_L phenotype (threshold of 1.24 um²/ms).

Treatment Arm	Variable	Coefficient	Hazard Ratio (95% C.I.)	P-Value
Bevacizumab Monotherapy	Age	−0.0072 ± 0.0172	0.9928 (0.9600 – 1.0268)	0.6742
	Volume (Continuous)	0.0461 ± 0.0131	1.0472 (1.0207 – 1.0744)	0.0004***
	ADC_L (1.24 um²/ms threshold)	−0.8365 ± 0.3875	0.4332 (0.2027 – 0.9260)	0.0309*

Lomustine Monotherapy	Age	0.0116 ± 0.0233	1.0116 (0.9665 – 1.0589)	0.6194
	Volume (Continuous)	0.0386 ± 0.0124	1.0394 (1.0143 – 1.0650)	0.0019**
	ADC_L (1.24 um²/ms threshold)	−0.4901 ± 0.3367	0.6126 (0.3166 – 1.1852)	0.1455